MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells. 2011

Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
Laboratory of Cancer and Developmental Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan, United States of America.

Mitogen-activated protein kinase kinases (MKK or MEK) 1 and 2 are usually treated as redundant kinases. However, in assessing their relative contribution towards ERK-mediated biologic response investigators have relied on tests of necessity, not sufficiency. In response we developed a novel experimental model using lethal toxin (LeTx), an anthrax toxin-derived pan-MKK protease, and genetically engineered protease resistant MKK mutants (MKKcr) to test the sufficiency of MEK signaling in melanoma SK-MEL-28 cells. Surprisingly, ERK activity persisted in LeTx-treated cells expressing MEK2cr but not MEK1cr. Microarray analysis revealed non-overlapping downstream transcriptional targets of MEK1 and MEK2, and indicated a substantial rescue effect of MEK2cr on proliferation pathways. Furthermore, LeTx efficiently inhibited the cell proliferation and anchorage-independent growth of SK-MEL-28 cells expressing MKK1cr but not MEK2cr. These results indicate in SK-MEL-28 cells MEK1 and MEK2 signaling pathways are not redundant and interchangeable for cell proliferation. We conclude that in the absence of other MKK, MEK2 is sufficient for SK-MEL-28 cell proliferation. MEK1 conditionally compensates for loss of MEK2 only in the presence of other MKK.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D001427 Bacterial Toxins Toxic substances formed in or elaborated by bacteria; they are usually proteins with high molecular weight and antigenicity; some are used as antibiotics and some to skin test for the presence of or susceptibility to certain diseases. Bacterial Toxin,Toxins, Bacterial,Toxin, Bacterial

Related Publications

Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
January 2015, Evidence-based complementary and alternative medicine : eCAM,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
December 2002, Muscle & nerve,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
May 2003, Oncogene,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
September 2001, Cancer research,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
June 2014, Oncology reports,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
April 1998, Clinical & experimental metastasis,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
December 2008, Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
November 2023, Physical review letters,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
January 1990, Human antibodies and hybridomas,
Chih-Shia Lee, and Karl J Dykema, and Danielle M Hawkins, and David M Cherba, and Craig P Webb, and Kyle A Furge, and Nicholas S Duesbery
May 2008, Journal of pharmaceutical sciences,
Copied contents to your clipboard!